LENSAR, Inc. (LNSR) Key Metrics

NASDAQ: LNSRValuation, returns, debt and efficiency ratios over 8 years.

LNSR valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$71.3M
Enterprise value
$76.7M
P/E (TTM)
32.2
Forward P/E
—
PEG ratio
—
Price / sales
1.2
10-yr median 1.8
Price / book
5.9
10-yr median 1.0
EV / EBITDA
—
Dividend yield
—
Beta
0.95

LNSR key metrics, 2018–2025

Fiscal year ended December 31, 2025 · U.S. dollars

LNSR valuation Price multiples at each fiscal year-end price.

Price / sales+23.6%
2.4
2025 · hover or tap a bar for each year
2020: 3.02021: 1.6 (−45.8%)2022: 0.9 (−47.8%)2023: 0.9 (+7.4%)2024: 1.9 (+110.8%)2025: 2.4 (+23.6%)
20182025
Free cash flow yield−8.4 pts
−10.7%
2025 · hover or tap a bar for each year
2020: −17.9%2021: −16.6% (+1.3 pts)2022: −49.8% (−33.2 pts)2023: −25.7% (+24.1 pts)2024: −2.4% (+23.3 pts)2025: −10.7% (−8.4 pts)
20182025

LNSR valuation history

Fiscal year-endToday8-year median

LNSR returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

LNSR debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

LNSR cash returned to shareholders

DividendsBuybacksFree cash flow

LNSR price vs earnings per share

Share price at year-endEPS (right axis)

LNSR key metrics

2018–2025
LENSAR, Inc. key metrics by fiscal year
20252024202320222021202020192018
Valuation
Market capitalization$139.1M$103.0M$38.5M$30.1M$56.2M$79.3M——
Enterprise value$123.8M$83.1M$16.8M$18.2M$27.8M$42.5M——
Price / sales2.41.90.90.91.63.0——
Price / book—5.50.80.71.01.2——
EV / sales2.11.60.40.50.81.6——
Earnings yield−24.6%−30.5%−37.4%−66.2%−34.9%−24.9%——
Free cash flow yield−10.7%−2.4%−25.7%−49.8%−16.6%−17.9%——
Dividend yield————0.0%2.3%——
Shareholder yield (dividends + buybacks)0.0%0.0%0.0%0.0%0.0%18.0%——
Share price at fiscal year-end$11.63$8.94$3.51$2.96$5.99$7.25——
Per share
Revenue per share$4.89$4.64$3.84$3.48$3.68$2.41$2.87—
Earnings per share−$2.87−$2.73−$1.31−$1.96−$2.09−$1.81−$1.38—
Operating cash flow per share−$1.24−$0.20−$0.88−$1.46−$0.96−$1.26−$1.18—
Free cash flow per share−$1.25−$0.21−$0.90−$1.47−$0.99−$1.29−$1.38—
Cash per share$1.50$1.95$2.19$1.44$3.37$3.71$0.43—
Book value per share−$2.18$1.62$4.30$4.13$5.85$6.15−$2.87—
Tangible book value per share−$2.61$1.09$3.30$2.94$4.69$5.04−$4.13—
Dividends per share————$0.00$0.17$0.00—
Capex per share$0.01$0.01$0.02$0.01$0.04$0.03$0.20—
Debt per share$0.23$0.23$0.21$0.28$0.35$0.35$1.93—
Shares outstanding12.0M11.5M11.0M10.2M9.4M10.9M10.6M—
Change in shares outstanding+3.8%+5.0%+8.0%+8.4%−14.3%+2.8%——
Returns & profitability
Return on equity (ROE)—−95.4%−32.3%−41.1%−32.1%−107.9%——
Return on invested capital (ROIC)——−34.8%−56.3%−54.5%−185.2%—−42.3%
Return on assets (ROA)−49.8%−46.2%−22.9%−32.6%−26.9%−34.8%−46.2%−43.6%
Return on tangible assets−51.8%−52.2%−24.6%−45.5%−35.3%−29.5%−69.2%−75.9%
Free cash flow margin−25.5%−4.5%−23.5%−42.3%−27.1%−53.7%−48.1%−21.0%
Financial health
Total debt$2.7M$2.6M$2.3M$2.8M$3.3M$3.8M$20.5M$41.2M
Cash & short-term investments$18.0M$22.5M$24.1M$14.7M$31.6M$40.6M$4.6M$3.3M
Net debt−$15.2M−$19.8M−$21.8M−$11.9M−$28.3M−$36.8M$15.9M$37.9M
Debt / equity—0.140.050.070.060.06——
Debt / assets0.040.040.030.050.050.050.591.43
Current ratio1.152.803.992.955.146.902.191.53
Quick ratio0.622.042.641.924.405.301.161.00
Interest coverage———-76.7-16.5-13.8-6.4—
Working capital$6.2M$27.0M$34.8M$22.3M$36.1M$49.9M$9.4M$4.1M
Invested capital−$41.3M−$1.2M$25.4M$30.1M$26.6M$30.4M−$14.6M$17.4M
Tangible asset value−$31.2M$12.5M$36.2M$29.9M$44.0M$55.1M−$43.9M−$32.8M
Net current asset value−$50.7M−$5.7M$24.0M$19.9M$33.2M$46.5M−$47.9M−$37.6M
Graham net-net per share−$5.35−$1.27$1.16$1.12$2.88$3.41−$5.03—
Capital allocation
Dividends paid————$0$1.9M$31,000$198,000
Share buybacks (net)$0$0$0$0$0$12.4M$13.2M—
Capex / revenue0.1%0.3%0.6%0.3%1.0%1.4%6.8%13.3%
Capex / depreciation0.020.040.070.030.130.140.540.71
Stock-based compensation / revenue5.4%5.0%13.1%18.7%19.9%34.3%0.3%5.4%
R&D / revenue9.6%10.0%14.6%33.4%35.9%28.6%24.8%11.4%
SG&A / revenue77.3%49.5%63.9%76.8%69.3%90.1%56.2%—
Efficiency
Days sales outstanding40.236.945.758.039.443.943.049.4
Days of inventory on hand192.0179.0237.7216.0219.1319.4127.9100.3
Days payables outstanding145.666.081.796.256.860.231.534.9
Cash conversion cycle (days)86.6149.9201.7177.8201.7303.1139.4114.9
Receivables turnover9.099.907.986.309.268.328.497.39
Payables turnover2.515.534.473.806.436.0711.5810.47
Inventory turnover1.902.041.541.691.671.142.853.64
Asset turnover0.850.790.670.580.470.460.960.84
Average receivables$6.4M$5.4M$5.3M$5.6M$3.7M$3.2M$3.6M$3.3M
Average payables$12.5M$5.0M$4.7M$4.1M$2.6M$2.0M$1.5M$1.4M
Average inventory$16.5M$13.6M$13.7M$9.1M$10.0M$10.8M$6.1M$4.1M
Intangibles / total assets7.3%9.2%15.8%21.7%16.4%15.3%38.7%42.6%

Computed from LNSR's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

LNSR valuation and financial ratios

Based on the latest twelve months, the trailing P/E is 32.2. It ended the year with $2.7 million of debt and $18.0 million in cash and short-term investments, a net cash position of $15.2 million.

See the LNSR income statement, the LNSR chart for price history, or the LNSR stock overview for the latest quote and news.

LNSR key metrics FAQ

What is LENSAR's P/E ratio?

LENSAR's trailing P/E ratio is 32.2 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.

How much debt does LENSAR have?

LENSAR had total debt of $2.7 million at the end of fiscal 2025 and more cash than debt.

What is LENSAR's free cash flow yield?

LENSAR generated -$14.9 million of free cash flow in fiscal 2025, a free cash flow yield of −10.7% on its market value at year-end ($139.1 million).

What is LENSAR's current ratio?

LENSAR's current ratio was 1.15 at the end of fiscal 2025: current assets were 1.15 times current liabilities.

Medical Devices key metrics